AVEVA Drug Delivery Systems, Inc. 2023-03-22 Health moderate FDA
Health · FDA · Recall #FDA-D-0465-2023
Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of… Recall
Issued March 22, 2023 · AVEVA Drug Delivery Systems, Inc.
In March 2023, AVEVA Drug Delivery Systems, Inc. recalled the Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of…, a moderate health recall reported by the FDA.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Failed Impurities/Degradation Specifications: Out of specification for related substance 10-hydroxy buprenorphine N-Oxide results generated at the 18-month stability timepoint.
What you should do
- 1 Stop using Buprenorphine Transdermal System, CIII 10 mcg/hour, 4 Transdermal Systems One package of… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact AVEVA Drug Delivery Systems, Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- AVEVA Drug Delivery Systems, Inc.
- Category
- Health
- Recall date
- March 22, 2023
- Units affected
- Not reported
- Sold at
- Nationwide
- Recall number
- FDA-D-0465-2023
- Made in
- United States
- Issuing agency
- FDA
In context
- AVEVA Drug Delivery Systems, Inc. has 2 recalls in our database.
- We're tracking 3,576 Health recalls in our database.
- This is the 903rd Health recall we've logged in 2023.